clinical trial glp 1 Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment The GLP-1 muscle loss headlines

Due to the structure and absorption of D-allulose, there was interest from the beginning of human studies on the tolerability of D-allulose

Ferr S, Fredholm BB, Morelli M, Popoli P, Fuxe K

No severe or confirmed hypoglycaemic episodes were reported in the two trials and there were no clinically relevant observations related to vital signs, physical examination, electrocardiogram or laboratory safety parameters, except temporary asymptomatic increases in lipase levels in two subjects at follow-up in the dosing conditions trial (from 46 U/L at screening to 231 U/L at follow-up and from 59 U/L at screening to 378 U/L at follow-up [normal range 1360 U/L])

Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape

Semaglutide is the active ingredient in Ozempic and Wegovy

At least one reviewer notes finding more reasonably priced GLP-1 prescribers elsewhere, indicating the platforms pricing is competitive but not the lowest in the market for all dose levels